Close Menu

The drug discovery and development company Exelixis will be laying off 270 people, or 40 percent of its workforce, reports the San Francisco Business Times. The company's drug discovery group will bear the brunt of the cuts. The company says that having lower compensation, lab supplies and clinical trial costs will save it $90 million through 2011.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.